Advertisement RedHill secures authorization in Australia and New Zealand for ongoing Phase III Crohn's disease trial with RHB-104 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

RedHill secures authorization in Australia and New Zealand for ongoing Phase III Crohn’s disease trial with RHB-104

RedHill Biopharma, an Israeli biopharmaceutical company, has received regulatory authorization to commence patient enrollment in Australia and New Zealand for its ongoing Phase III study with RHB-104 for Crohn's disease (the MAP US study), and has commenced patient screening in New Zealand.

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties.

The MAP US study is the first Phase III study with RHB-104 for the treatment of Crohn’s disease, currently ongoing in the U.S. and additional countries. With over 80 of the 120 planned clinical sites already active worldwide, the ongoing randomized, double-blind, placebo-controlled MAP US study is expected to enroll 270 patients with moderately to severely active Crohn’s disease.

Patients are randomized 1:1 to receive either RHB-104 or a placebo for 52 weeks and evaluated for the primary endpoint of remission at week 26 of treatment. Interim analysis of the MAP US study is expected in the second half of 2016 after half of the patients expected to be enrolled in the study will have completed 26 weeks of treatment.

The MAP US Phase III study is registered on www.ClinicalTrials.gov, a web-based service of the U.S. National Institutes of Health, which provides access to information on publicly and privately supported clinical studies: https://www.clinicaltrials.gov/ct2/show/NCT01951326.

Dror Ben-Asher, RedHill’s CEO, said: "The addition of Australia and New Zealand to RHB-104’s Phase III Crohn’s study, currently ongoing in the U.S. and additional countries, should further boost the study’s reach and pace. We are particularly excited about the addition of these two countries because the RHB-104 formulation was originally developed in Australia by Professor Thomas Borody, a leading innovator of therapeutic approaches for GI diseases, and an Australian Phase III study was conducted by Pfizer with an earlier formulation of the drug."

RedHill also plans to initiate a second Phase III study of RHB-104 for Crohn’s disease (the MAP EU study) and has recently announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted RedHill’s Clinical Trial Application (CTA) to initiate the MAP EU study.

The MAP EU study is planned to commence in a select number of European countries and, once initiated, will run in parallel with the currently ongoing MAP US study.

The randomized, double-blind, placebo-controlled MAP EU Phase III study is expected to enroll 360 patients with moderately active Crohn’s disease. Patients will be randomized 2:1 to receive either RHB-104 or a placebo for 52 weeks and then evaluated for remission at week 26 as the primary endpoint.

Currently in a first Phase III study for the treatment of Crohn’s disease (the MAP US study) and a second Phase III study being prepared (the MAP EU study), RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties.

RHB-104 is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by the Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. Clinical trials conducted with earlier formulations of RHB-104 include an Australian Phase III study conducted by Pfizer.

RedHill has conducted several supportive studies with the current formulation of RHB-104 and a long-term population pharmacokinetic (Pop-PK) study is ongoing as part of the Phase III MAP US study.

RHB-104 is covered by several issued and pending patents. RedHill is also conducting a Phase IIa, proof-of-concept clinical study, evaluating RHB-104 as an add-on therapy to interferon beta-1a in patients treated for relapsing-remitting multiple sclerosis (RRMS).